Suven Pharma sets effective date, record date for Cohance merger
Suven Pharmaceuticals Limited (BSE: SUVENPHAR) announced that the Scheme of Amalgamation with Cohance Lifesciences Limited will be effective from May 1, 2025. This follows the approval and sanction by the National Company Law Tribunal, Mumbai bench, on March 27, 2025. The company has also set May 8, 2025, as the record date to determine the shareholders of Cohance Lifesciences who will receive equity shares of Suven Pharmaceuticals. The share exchange ratio is set at 11 fully paid-up equity shares of Suven Pharmaceuticals, with a face value of INR1 each, for every 295 fully paid-up equity shares of Cohance Lifesciences, with a face value of INR10 each. The effective date and record date are in accordance with the Scheme of Amalgamation, the Appointed Date of the merger is the same as the Effective Date, i.e., May 1, 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when SUVEN PHARMACEUTICALS publishes news
Free account required • Unsubscribe anytime